Developer docs
API playgroundTry for free, no card

Search company profiles

Lifeward

Full company profile

uuid00024r4

Namestring
Lifeward
Legal namestring
Lifeward Ltd.
Websiteurl
golifeward.com
Company typeenum
Public
Founded yearint
2001
Descriptiontext

Lifeward Ltd. (NASDAQ: LFWD), formerly ReWalk Robotics, is a publicly traded medical device company founded in 2001 that develops wearable robotic exoskeletons and rehabilitation technologies for individuals with lower limb disabilities. The company is domiciled in Israel with US headquarters in Marlborough, Massachusetts, a German subsidiary (Lifeward GmbH, Berlin), and a California operation (Lifeward CA, Inc., formerly AlterG), serving patients with spinal cord injuries, stroke, multiple sclerosis, brain injuries, and orthopedic conditions across the United States, Europe, Israel, and select international markets through channel partners.

The company's portfolio comprises four FDA-cleared hardware platforms: the ReWalk Personal Exoskeleton (now in its seventh generation, the first FDA-cleared personal exoskeleton with stair and curb navigation), the AlterG Anti-Gravity Systems (pressurized air-chamber treadmills using NASA-derived Differential Air Pressure technology), the ReStore Exo-Suit (the first FDA-cleared exo-suit for post-stroke gait training), and MYOLYN Functional Electrical Stimulation cycling systems. In early 2026 Lifeward expanded into biotech through the acquisition of Oratech Pharmaceuticals and the clinical-stage Protein Oral Delivery (POD) platform, targeting oral delivery of pharmaceutical proteins currently administered by injection. The company holds ISO 13485 and FDA 21 CFR Part 820 quality system certifications, FDA clearances for each device line, and CE Mark approval for ReWalk 7.

Lifeward monetizes through direct hardware sales to healthcare facilities and qualifying patients, supplemented by a 4% royalty stream from Oramed on ReWalk franchise net sales for up to 10 years. Pricing follows a unit hardware model across product tiers (MyoCycle Home/Pro, AlterG NEO/PRO, ReWalk Personal Exoskeleton). Patient access is facilitated by Medicare, Medicare Advantage plans (Aetna, Humana, UnitedHealthcare covering approximately 16 million lives), VA benefits, and workers' compensation, supported by an in-house reimbursement team. Distribution combines direct enterprise field sales, a network of 300+ certified clinical training partners, exclusive international distributors such as Verita Neuro for Mexico, Thailand, UAE, and Singapore, and direct-to-patient engagement. FY2025 revenue totaled $22.03 million against a net loss of $19.9 million.

Short descriptiontext

Lifeward is a publicly traded medical device company developing FDA-cleared robotic exoskeletons, anti-gravity treadmills, exo-suits, and FES cycling systems for rehabilitation of patients with spinal cord injury, stroke, multiple sclerosis, and orthopedic conditions, distributing through healthcare providers, the VA, and Medicare Advantage payers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMarlborough, United States
HQ citystring
Marlborough
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable robotic exoskeletons, rehabilitation medical devices, anti-gravity treadmills, functional electrical stimulation, neurorehabilitation robotics
Industry4 codes
PRIMARYHLAHAEAH
Limb Prosthetics (Upper/Lower Extremity Prosthetic Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAMAJ
Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHLAHAMAG
Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHSADAIAN
Prosthetics/Orthotics Rehab & Amputee Rehabilitation
Home & Personal Services/Fitness, Wellness & Personal Training/Physical Therapy, Rehabilitation & Corrective Exercise
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Rehabilitation Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of FDA-cleared medical devices including ReWalk Personal Exoskeleton, AlterG Anti-Gravity Systems, ReStore Exo-Suit, and MyoCycle FES bikes. Devices are sold to healthcare facilities, rehabilitation centers, and directly to qualifying patients with insurance coverage or self-pay arrangements.

golifeward.com
2Clinical Trial Management Services
TypeProfessional Services
Description

Oramed retains responsibility for managing and funding the POD clinical program under a clinical trial management agreement, while Lifeward focuses on MedTech profitability

globenewswire.com
3Royalty Revenue
TypeLicensing Royalties
Description

Oramed receives 4% royalties on ReWalk franchise net sales for up to 10 years as part of the strategic partnership agreement

globenewswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
Pricing details7 tiers
1MyoCycle Home - Basic FES cycling for home use
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Entry-level model with 6 stimulation channels and cycling gait mode, automated setup

golifeward.com
2MyoCycle Home Plus - Enhanced FES cycling with walking gait capability
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

10-channel stimulation with both cycling and walking gait modes, automated control

golifeward.com
3MyoCycle Pro - Clinical-grade FES cycling system
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

6-channel with automatic and manual control modes, MyoPortal database access, clinical training included

golifeward.com
4MyoCycle Pro Plus - Full-featured clinical FES system
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

10-channel with dual control modes, unlimited user profiles, MyoPortal database, clinical training included

golifeward.com
5AlterG NEO - Entry-level anti-gravity treadmill
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Accessible price-point anti-gravity treadmill using differential air pressure technology

golifeward.com
6AlterG NEO+ - Advanced anti-gravity treadmill with analytics
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Live video monitoring, high-speed performance options, real-time gait analytics

golifeward.com
7AlterG PRO - Premium anti-gravity treadmill
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Most robust unweighted recovery and performance training solution for extreme speeds and training conditions

golifeward.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ReWalk
Description

FDA-approved personal exoskeleton system for individuals with spinal cord injury

golifeward.com
+3 more records
Core offering1 text field

Lifeward designs, manufactures, and sells FDA-cleared wearable robotic exoskeletons, soft robotic exo-suits, anti-gravity treadmill systems, and functional electrical stimulation (FES) cycling devices used by individuals with spinal cord injuries, stroke survivors, and other patients requiring physical rehabilitation. The company sells its medical devices to rehabilitation hospitals, clinical training centers, and directly to qualifying patients through insurance coverage including Medicare, Medicare Advantage, VA benefits, and workers' compensation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 800+ ReWalk Personal Exoskeletons in use worldwide
+3 more records
Product overview1 text field

Lifeward is a diversified biomedical innovation company offering a portfolio of FDA-cleared medical devices for physical rehabilitation. The product portfolio consists of four core product lines: the ReWalk Personal Exoskeleton (wearable robotic exoskeleton for spinal cord injury patients), the AlterG Anti-Gravity Systems (pressurized air treadmills for unweighted training), the MYOLYN FES Cycling systems (functional electrical stimulation bikes), and the ReStore Exo-Suit (exo-suit for post-stroke rehabilitation). In 2026, Lifeward expanded into biotech through the acquisition of Oramed's Protein Oral Delivery (POD) technology. Founded in 2001 (formerly ReWalk Robotics), the company operates in the United States, Israel, and Germany.

Product and service5 records
1ReWalk Personal Exoskeleton
CategoryWearable Robotic Exoskeleton
Description

A wearable robotic exoskeleton (now in its seventh generation, ReWalk 7) that enables individuals with spinal cord injury to stand upright, walk, turn, and climb/descend stairs through powered hip and knee motion, with crutch-based control, multiple walking speeds, and a companion mobile app for progress tracking.

2AlterG Anti-Gravity Systems
CategoryAnti-Gravity Rehabilitation Treadmill
Description

Treadmills with pressurized air chambers using NASA Differential Air Pressure (DAP) technology to reduce gravitational load in precise 1% increments, enabling patients and athletes to move unrestricted and pain-free for rehabilitation and performance training. Includes NEO and PRO series variants.

3MYOLYN FES Cycling
CategoryFunctional Electrical Stimulation
Description

Functional Electrical Stimulation (FES) bikes providing therapeutic cycling for clinic and home use. The MyoCycle product line includes Home, Home Plus, Pro, and Pro Plus models with 6- or 10-channel stimulation, cycling and walking gait modes, automated setup, and MyoPortal database access.

4ReStore Exo-Suit
CategorySoft Robotic Exo-Suit
Description

A soft robotic gait-training exo-suit using cable-driven actuation designed to promote restoration of functional walking patterns post-stroke; the first FDA-cleared exo-suit for rehabilitating walking ability after stroke.

5Protein Oral Delivery (POD) Technology
CategoryOral Protein Drug Delivery
Description

Clinical-stage protein oral delivery technology acquired from Oramed Pharmaceuticals that enables pharmaceutical proteins (such as insulin) to be delivered as oral pills rather than injections.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Transformative strategic partnership involving Lifeward acquiring Oramed's clinical-stage Protein Oral Delivery (POD) technology while Oramed acquires up to 49.99% equity ownership in Lifeward. Investment provides Lifeward access to up to $47 million through equity, convertible notes, milestone-based funding, and warrant coverage. Oramed retains responsibility for managing and funding the POD clinical program including a planned 60-patient U.S. clinical trial for oral insulin candidate ORMD-0801.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-17
Description

Exclusive distribution partnership for ReWalk Personal Exoskeleton in Mexico, Thailand, and UAE. Verita Neuro will integrate the exoskeleton into its neurorehabilitation programs and leverage its extensive patient database to facilitate clinical adoption.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Ekso Bionics is the most direct competitor to Lifeward, developing and commercializing powered exoskeletons (EksoNR, Ekso Indego) for stroke, SCI, and neurological rehabilitation in clinical settings. Both companies compete for the same clinician customers and reimbursement pathways.

TypeDirect peer
Description

Myomo develops myoelectric orthotic devices (MyoPro) for individuals with arm paralysis and weakness. While focused on upper extremity, Myomo targets overlapping patient populations (stroke, SCI, MS) and similar payer reimbursement channels as Lifeward.

TypeEmerging player
Description

Fourier Intelligence is a Chinese-based rehabilitation robotics company developing exoskeleton and gait training systems. As an emerging global player, it represents competitive pressure particularly in APAC markets and price-sensitive segments that Lifeward addresses.

4Bionik Laboratories
TypeEmerging player
Description

Bionik Laboratories is a smaller rehabilitation robotics company developing the InMotion ARM and InMotion WALK products for upper and lower extremity therapy. As an emerging player, it competes in adjacent portions of the neurorehabilitation robotics market served by Lifeward.

TypeDirect peer
Description

CYBERDYNE develops the HAL (Hybrid Assistive Limb) robotic exoskeleton series for medical and industrial applications, including FDA-cleared versions for SCI in the US. CYBERDYNE competes in the same wearable robotic exoskeleton category as Lifeward globally.

TypeDirect peer
Description

Parker Hannifin's Indego division produces FDA-cleared powered exoskeletons for SCI and stroke rehabilitation, directly competing with ReWalk Personal Exoskeleton and ReStore Exo-Suit. Both target the same VA, Medicare, and clinical rehabilitation channels.

TypeBroad incumbent
Description

Ottobock is the global leader in prosthetics, orthotics, and exoskeleton technology (including acquired SuitX). While a much larger incumbent, Ottobock competes directly in the wearable robotic exoskeleton space and has the resources to pressure Lifeward's market position.

8Hocoma (DIH Medical)
TypeDirect peer
Description

Hocoma, now part of DIH Medical, is a leading provider of robotic rehabilitation devices including the Lokomat gait trainer and Armeo robotic arm. Hocoma competes with Lifeward's ReStore exo-suit and AlterG systems in the clinical neurorehabilitation market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds21 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lifeward

Rehabilitation Medical Devicesgolifeward.com

Lifeward is a publicly traded medical device company developing FDA-cleared robotic exoskeletons, anti-gravity treadmills, exo-suits, and FES cycling systems for rehabilitation of patients with spinal cord injury, stroke, multiple sclerosis, and orthopedic conditions, distributing through healthcare providers, the VA, and Medicare Advantage payers.

What Lifeward does

Lifeward Ltd. (NASDAQ: LFWD), formerly ReWalk Robotics, is a publicly traded medical device company founded in 2001 that develops wearable robotic exoskeletons and rehabilitation technologies for individuals with lower limb disabilities. The company is domiciled in Israel with US headquarters in Marlborough, Massachusetts, a German subsidiary (Lifeward GmbH, Berlin), and a California operation (Lifeward CA, Inc., formerly AlterG), serving patients with spinal cord injuries, stroke, multiple sclerosis, brain injuries, and orthopedic conditions across the United States, Europe, Israel, and select international markets through channel partners.

The company's portfolio comprises four FDA-cleared hardware platforms: the ReWalk Personal Exoskeleton (now in its seventh generation, the first FDA-cleared personal exoskeleton with stair and curb navigation), the AlterG Anti-Gravity Systems (pressurized air-chamber treadmills using NASA-derived Differential Air Pressure technology), the ReStore Exo-Suit (the first FDA-cleared exo-suit for post-stroke gait training), and MYOLYN Functional Electrical Stimulation cycling systems. In early 2026 Lifeward expanded into biotech through the acquisition of Oratech Pharmaceuticals and the clinical-stage Protein Oral Delivery (POD) platform, targeting oral delivery of pharmaceutical proteins currently administered by injection. The company holds ISO 13485 and FDA 21 CFR Part 820 quality system certifications, FDA clearances for each device line, and CE Mark approval for ReWalk 7.

Lifeward monetizes through direct hardware sales to healthcare facilities and qualifying patients, supplemented by a 4% royalty stream from Oramed on ReWalk franchise net sales for up to 10 years. Pricing follows a unit hardware model across product tiers (MyoCycle Home/Pro, AlterG NEO/PRO, ReWalk Personal Exoskeleton). Patient access is facilitated by Medicare, Medicare Advantage plans (Aetna, Humana, UnitedHealthcare covering approximately 16 million lives), VA benefits, and workers' compensation, supported by an in-house reimbursement team. Distribution combines direct enterprise field sales, a network of 300+ certified clinical training partners, exclusive international distributors such as Verita Neuro for Mexico, Thailand, UAE, and Singapore, and direct-to-patient engagement. FY2025 revenue totaled $22.03 million against a net loss of $19.9 million.

Lifeward firmographics

Firmographics
Name
Lifeward
Legal name
Lifeward Ltd.
Website
https://golifeward.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Short description
Lifeward is a publicly traded medical device company developing FDA-cleared robotic exoskeletons, anti-gravity treadmills, exo-suits, and FES cycling systems for rehabilitation of patients with spinal cord injury, stroke, multiple sclerosis, and orthopedic conditions, distributing through healthcare providers, the VA, and Medicare Advantage payers.
Ownership category
akta.pro rank

Lifeward industry classification

Industry
Product category
Rehabilitation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAH
Limb Prosthetics (Upper/Lower Extremity Prosthetic Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAMAJ
Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHLAHAMAG
Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHSADAIAN
Prosthetics/Orthotics Rehab & Amputee Rehabilitation
Home & Personal Services/Fitness, Wellness & Personal Training/Physical Therapy, Rehabilitation & Corrective Exercise

Keywords

  • Wearable robotic exoskeletons
  • Rehabilitation medical devices
  • Anti-gravity treadmills
  • Functional electrical stimulation
  • Neurorehabilitation robotics

Where Lifeward is headquartered

Location

Headquarters

HQ city
Marlborough
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Lifeward business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Sales: Sale of FDA-cleared medical devices including ReWalk Personal Exoskeleton, AlterG Anti-Gravity Systems, ReStore Exo-Suit, and MyoCycle FES bikes. Devices are sold to healthcare facilities, rehabilitation centers, and directly to qualifying patients with insurance coverage or self-pay arrangements.
  2. Clinical Trial Management Services: Oramed retains responsibility for managing and funding the POD clinical program under a clinical trial management agreement, while Lifeward focuses on MedTech profitability
  3. Royalty Revenue: Oramed receives 4% royalties on ReWalk franchise net sales for up to 10 years as part of the strategic partnership agreement

Pricing tiers

ModelBillingPrice
Unit PricingOne time/ perpetual licenseMyoCycle Home - Basic FES cycling for home use
Unit PricingOne time/ perpetual licenseMyoCycle Home Plus - Enhanced FES cycling with walking gait capability
Unit PricingOne time/ perpetual licenseMyoCycle Pro - Clinical-grade FES cycling system
Unit PricingOne time/ perpetual licenseMyoCycle Pro Plus - Full-featured clinical FES system
Unit PricingOne time/ perpetual licenseAlterG NEO - Entry-level anti-gravity treadmill
Unit PricingOne time/ perpetual licenseAlterG NEO+ - Advanced anti-gravity treadmill with analytics
Unit PricingOne time/ perpetual licenseAlterG PRO - Premium anti-gravity treadmill

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Lifeward product offering

Product offering

Core offering

Lifeward designs, manufactures, and sells FDA-cleared wearable robotic exoskeletons, soft robotic exo-suits, anti-gravity treadmill systems, and functional electrical stimulation (FES) cycling devices used by individuals with spinal cord injuries, stroke survivors, and other patients requiring physical rehabilitation. The company sells its medical devices to rehabilitation hospitals, clinical training centers, and directly to qualifying patients through insurance coverage including Medicare, Medicare Advantage, VA benefits, and workers' compensation.

Product overview

Lifeward is a diversified biomedical innovation company offering a portfolio of FDA-cleared medical devices for physical rehabilitation. The product portfolio consists of four core product lines: the ReWalk Personal Exoskeleton (wearable robotic exoskeleton for spinal cord injury patients), the AlterG Anti-Gravity Systems (pressurized air treadmills for unweighted training), the MYOLYN FES Cycling systems (functional electrical stimulation bikes), and the ReStore Exo-Suit (exo-suit for post-stroke rehabilitation). In 2026, Lifeward expanded into biotech through the acquisition of Oramed's Protein Oral Delivery (POD) technology. Founded in 2001 (formerly ReWalk Robotics), the company operates in the United States, Israel, and Germany.

Differentiator

Problem solved

Functional benefit

Brands

  • ReWalk: FDA-approved personal exoskeleton system for individuals with spinal cord injury
  • AlterG
  • MYOLYN
  • ReStore

Products and services

  • ReWalk Personal Exoskeleton A wearable robotic exoskeleton (now in its seventh generation, ReWalk 7) that enables individuals with spinal cord injury to stand upright, walk, turn, and climb/descend stairs through powered hip and knee motion, with crutch-based control, multiple walking speeds, and a companion mobile app for progress tracking.
  • AlterG Anti-Gravity Systems Treadmills with pressurized air chambers using NASA Differential Air Pressure (DAP) technology to reduce gravitational load in precise 1% increments, enabling patients and athletes to move unrestricted and pain-free for rehabilitation and performance training. Includes NEO and PRO series variants.
  • MYOLYN FES Cycling Functional Electrical Stimulation (FES) bikes providing therapeutic cycling for clinic and home use. The MyoCycle product line includes Home, Home Plus, Pro, and Pro Plus models with 6- or 10-channel stimulation, cycling and walking gait modes, automated setup, and MyoPortal database access.
  • ReStore Exo-Suit A soft robotic gait-training exo-suit using cable-driven actuation designed to promote restoration of functional walking patterns post-stroke; the first FDA-cleared exo-suit for rehabilitating walking ability after stroke.
  • Protein Oral Delivery (POD) Technology Clinical-stage protein oral delivery technology acquired from Oramed Pharmaceuticals that enables pharmaceutical proteins (such as insulin) to be delivered as oral pills rather than injections.

Quantifiable outcome

  • 800+ ReWalk Personal Exoskeletons in use worldwide
  • +3 more outcomes

Companies that use Lifeward

Customer profile

Named customers8 records

Segments6 records

Ideal customer profiles4 records

Lifeward technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Lifeward partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and regional.

  • Oramed PharmaceuticalscoreStrategic or Co-development Partner · 13 January 2026Transformative strategic partnership involving Lifeward acquiring Oramed's clinical-stage Protein Oral Delivery (POD) technology while Oramed acquires up to 49.99% equity ownership in Lifeward. Investment provides Lifeward access to up to $47 million through equity, convertible notes, milestone-based funding, and warrant coverage. Oramed retains responsibility for managing and funding the POD clinical program including a planned 60-patient U.S. clinical trial for oral insulin candidate ORMD-0801.
  • Verita NeuroregionalChannel Partner/ Reseller/ Distributor · 17 December 2025Exclusive distribution partnership for ReWalk Personal Exoskeleton in Mexico, Thailand, and UAE. Verita Neuro will integrate the exoskeleton into its neurorehabilitation programs and leverage its extensive patient database to facilitate clinical adoption.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Lifeward competitors and assessment

Company assessment

Direct peers

  • Ekso Bionics: Ekso Bionics is the most direct competitor to Lifeward, developing and commercializing powered exoskeletons (EksoNR, Ekso Indego) for stroke, SCI, and neurological rehabilitation in clinical settings. Both companies compete for the same clinician customers and reimbursement pathways.
  • Myomo: Myomo develops myoelectric orthotic devices (MyoPro) for individuals with arm paralysis and weakness. While focused on upper extremity, Myomo targets overlapping patient populations (stroke, SCI, MS) and similar payer reimbursement channels as Lifeward.
  • CYBERDYNE: CYBERDYNE develops the HAL (Hybrid Assistive Limb) robotic exoskeleton series for medical and industrial applications, including FDA-cleared versions for SCI in the US. CYBERDYNE competes in the same wearable robotic exoskeleton category as Lifeward globally.
  • Parker Hannifin (Indego): Parker Hannifin's Indego division produces FDA-cleared powered exoskeletons for SCI and stroke rehabilitation, directly competing with ReWalk Personal Exoskeleton and ReStore Exo-Suit. Both target the same VA, Medicare, and clinical rehabilitation channels.
  • Hocoma (DIH Medical): Hocoma, now part of DIH Medical, is a leading provider of robotic rehabilitation devices including the Lokomat gait trainer and Armeo robotic arm. Hocoma competes with Lifeward's ReStore exo-suit and AlterG systems in the clinical neurorehabilitation market.

Emerging players

  • Fourier Intelligence: Fourier Intelligence is a Chinese-based rehabilitation robotics company developing exoskeleton and gait training systems. As an emerging global player, it represents competitive pressure particularly in APAC markets and price-sensitive segments that Lifeward addresses.
  • Bionik Laboratories: Bionik Laboratories is a smaller rehabilitation robotics company developing the InMotion ARM and InMotion WALK products for upper and lower extremity therapy. As an emerging player, it competes in adjacent portions of the neurorehabilitation robotics market served by Lifeward.

Broad incumbents

  • Ottobock: Ottobock is the global leader in prosthetics, orthotics, and exoskeleton technology (including acquired SuitX). While a much larger incumbent, Ottobock competes directly in the wearable robotic exoskeleton space and has the resources to pressure Lifeward's market position.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Lifeward social profiles

Digital presence

Lifeward compliance and trust

Trust signal

Compliance3 records

Lifeward financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lifeward leadership team

Management profile

Number of profiles

Profiles9 records

Lifeward subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Lifeward funding detail

Funding detail

Funding overview

Funding rounds21 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lifeward M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lifeward

What does Lifeward do?

Lifeward designs, manufactures, and sells FDA-cleared wearable robotic exoskeletons, soft robotic exo-suits, anti-gravity treadmill systems, and functional electrical stimulation (FES) cycling devices used by individuals with spinal cord injuries, stroke survivors, and other patients requiring physical rehabilitation. The company sells its medical devices to rehabilitation hospitals, clinical training centers, and directly to qualifying patients through insurance coverage including Medicare, Medicare Advantage, VA benefits, and workers' compensation.

Is Lifeward a public or private company?

Lifeward is a public company. It is classified as public and is currently operating.

When was Lifeward founded?

Lifeward was founded in 2001. It employs 51 to 100 people.

Where is Lifeward based?

Lifeward is headquartered in Marlborough, United States, in the North America region.

How does Lifeward make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are clinical Trial Management Services and royalty Revenue.

Who are Lifeward's main competitors?

Direct peers on record are Ekso Bionics, Myomo, CYBERDYNE, Parker Hannifin (Indego) and Hocoma (DIH Medical). Emerging players are Fourier Intelligence and Bionik Laboratories. Ottobock is listed as a broad incumbent.

Does Lifeward have an API?

No public API is recorded for Lifeward.

What industry is Lifeward in?

Lifeward's product category is Rehabilitation Medical Devices. Its primary akta.pro industry code is HLAHAEAH, Limb Prosthetics (Upper/Lower Extremity Prosthetic Systems), with a secondary code of HLAHAMAJ, Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics). Its NAICS code is 334510 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestegateLifeward Brings $22M Revenue, Reimbursed Robotics and an AI Pipeline to an $11.5M Market Cap (NASDAQ: LFWD)Lifeward reported $22 million in 2025 revenue, with AlterG alone generating $12.9 million, yet its equity value is about $11.5 million. The company has a Medicare reimbursement pathway for ReWalk and an AI-powered exoskeleton pipeline. A new leadership team is pursuing a partner-based distribution strategy.Business & FinancialLifeward Brings $22M Revenue, Reimbursed Robotics And An AI Pipeline To An $11.5M Market Cap (NASDAQ: LFWD)Lifeward reported $22 million in 2025 revenue, with AlterG alone generating $12.9 million and double-digit growth. The company's equity value is about $11.5 million, and it has a Medicare reimbursement pathway for ReWalk and an AI-powered exoskeleton pipeline. New leadership aims to expand distribution and commercial execution.TradingViewHC Wainwright & Co. maintains Lifeward at Buy, lowers price target to $8 from $10HC Wainwright & Co. maintained Lifeward at Buy and lowered its price target to $8 from $10, a 20% cut. The target implies a 97% upside from the Nov 13 close of $4.06.Quiver QuantitativeLifeward Ltd. (LFWD) Stock Falls on Q3 2026 Earnings | LFWD Stock NewsLifeward Ltd. reported Q3 2026 revenue of $5.4 million, down 12% year-over-year, with an operating loss of $6.0 million and net loss of $5.1 million. The stock fell 3.1% in morning trading. Government contract awards totaled $643,683 over the past year.TradingViewLifeward Reports Q3 Revenue of $5.4 Million and Net Loss of $5.1 MillionLifeward reported Q3 2026 revenue of $5.4 million, down 12% year over year, and a net loss of $5.1 million. Gross margin fell to 27.4% from 43.7% a year earlier, and operating loss was $6.0 million. The company is shifting ReWalk to a channel-partner distribution model and developing an AI-enabled upper-body exoskeleton.TradingViewLifeward Ltd. (LFWD) Q3 Revenue Falls 12% To $5.4MLifeward Ltd. reported Q3 2026 revenue of $5.4 million, down 12% year over year from $6.2 million, with a net loss of $5.1 million versus $3.2 million. Cash increased to $4.5 million from $2.2 million at year-end 2025, but gross margin compressed to 27.4% from 43.7%.Stock TitanLifeward Q3 earnings: revenue falls 12% to $5.4MLifeward reported Q3 2026 revenue of $5.4 million, down 12% year-over-year, with AlterG revenue up 18% to $3.6 million and ReWalk revenue down to $1.7 million. The company is transitioning ReWalk to a channel-partner distribution model, which is expected to reduce operating expenses and accelerate cash collection.Worcester Business JournalLifeward hires finance veteran as next CFO amid cash crunchLifeward hired Ronen Tsimerman as CFO, effective Nov. 1, following the departure of Almog Adar. The company's Q2 filing disclosed a going concern warning, citing $9.4 million in cash insufficient for 12 months of operations.FinanzNachrichten.de6,4 Millionen US-Dollar pro Patient: Warum Medtronic, Lifeward und NurExone an drei Stufen der Rückenmarksversorgung ansetzenMedtronic, Lifeward, and NurExone address spinal cord injury at three stages: surgical stabilization, exoskeleton rehabilitation, and early biological repair. The US National Spinal Cord Injury Statistical Center estimates direct lifetime costs at $6.4 million per patient. NurExone's ExoPTEN candidate targets early neuroprotection, with clinical development planned.MarketWatchLifeward's Pick for CFO Withdraws From PositionRami Aviram, Lifeward's appointed CFO, withdrew from the position, effective Nov. 1. Interim CFO Josh Hexter will continue until a successor is named. Lifeward is searching for a permanent financial chief.